Vonoprazan FuMarate Chemical Properties

storage temp. 

Store at -20°C

solubility 

DMSO: 50 mg/mL (108.35 mM)

form 

Solid

color 

White to Off-White

InChIKey

ROGSHYHKHPCCJW-WLHGVMLRSA-N

SMILES

C(/C(=O)O)=C\C(=O)O.S(C1=CN=CC=C1)(N1C=C(CNC)C=C1C1C=CC=CC=1F)(=O)=O

Vonoprazan FuMarate Usage And Synthesis

Chemical Properties

Vonoprazan fumarate is white to nearly white crystals or crystalline powder which melts at 194.8°C . It can be dissolved in dimethyl sulfoxide, but has limited solubility in N,N-dimethylacetamide, N,N-dimethylformamide, methanol, and water. It is only slightly soluble in ethanol (99.5%), and has very low solubility in 2-propanol, acetone, 1-octanol, and acetonitrile.

Uses

Vonoprazan Fumarate (CAS# 881681-01-2) is a useful research chemical and a ATPase potassium-competitive acid blocker.

benefits

Compared with traditional irreversible proton pump inhibitors (such as omeprazole, esomeprazole, etc.), Vonoprazan fumarate advantages:
① The onset of action is good, and the maximum acid-suppressing effect will be achieved on the first day of administration;
② Oral administration, not affected by gastric acid damage;
③It can improve the phenomenon of acid breakthrough at night.

General Description

Vonoprazan fumarate (TAK-438) is a new oral anti-gastric acid drug jointly launched by Takeda Pharmaceutical and Otsuka Pharmaceutical. It can be used for the treatment of erosive esophagitis, gastric ulcer and duodenal ulcer.

Mechanism of action

Vonoprazan fumarate is a potassium ion (K+) competitive acid blocker (P-CAB), which is a reversible proton pump inhibitor. It can inhibit the combination of K+ and H+-K+-ATPase (proton pump), so that secretion of gastric acid is terminated. Vonoprazan fumarate has a strong and lasting inhibitory effect on gastric acid secretion.

Synthesis

Vonoprazan FuMarate is prepared by the reaction of vonoprazan and (2E)-but-2-enedioic acid. The steps are as follows:
Step 1: (2E)-but-2-enedioic acid With sodium hydroxide In water at 50 - 60℃.
Step 2: vonoprazan In water; toluene at 25 - 35℃; Reagent/catalyst.
Add 730g of water and 73g of fumaric acid to a 2L reaction flask at 5060, stir and disperse, control the temperature between 5060, add 25g of hydrogen hydroxide dropwise to the fumaric acid suspension The solution of sodium and 300 g of water was gradually dissolved in the system during the dropwise addition, and the aqueous solution of compound was obtained and kept for use.Between 25 and 35°C, take half of the toluene solution of compound obtained in the previous step and put it into a 5L reaction flask, and add the aqueous solution of the above compound dropwise to it. During the dropwise addition, the system has a white solid precipitation. After the dropwise addition was completed, keep stirring for 2-4 hours, filter, and dry the filter cake at 50°C to obtain 131.32 g of white solid, the HPLC purity was 99.96%, and the yield was 94%.

Vonoprazan FuMarate(881681-01-2)Related Product Information

• 1H-Pyrrole-3-carbonitrile,5-(2-fluorophenyl)-1-(3-pyridinylsulfonyl)-
• 1-methylpyridin-1-ium-4-sulfonate
• 1-(5-(2-fluorophenyl)-1H-pyrrol-3-yl)-N-methylmethanamine
• 5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrole-3-carbaldehyde
• tert-Butyl 4-(6-((6-(1-butoxyvinyl)-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate
• Palbociclib
• 4-[6-(6-BROMO-8-CYCLOPENTYL-5-METHYL-7-OXO-7,8-DIHYDRO-PYRIDO[2,3-D]PYRIMIDIN-2-YLAMINO)-PYRIDIN-3-YL]-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Paroxetine
• PD0332991 Isethionate
• paroxetine Mesylate
• Esomeprazole
• R-(+)-Lansoprazole
• 2-PYRIMIDINAMINE, 4-(3,4-DIHYDRO-1-METHYL-2(1H)-ISOQUINOLINYL)-N-(4-FLUOROPHENYL)-5,6-DIMETHYL-, MONOHYDROCHLORIDE
• Pantoprazole
• Lansoprazole
• Omeprazole
• Vonoprazan fumarate
• Vonoprazan